ABBV is trading at $229.70, up 6.1% in pre-market, extending gains following its strategic acquisition of Apogee Therapeutics. - The pharmaceutical giant announced on June 22 a definitive agreement to acquire clinical-stage biotech Apogee Therapeutics for approximately $10.9 billion, bolstering its immunology portfolio. - This major deal, AbbVie's largest in over five years, aims to diversify its revenue base and add promising immunology and inflammation assets, including a potential "mega-blockbuster" atopic dermatitis treatment. - The stock's current upward trajectory follows a significant 6.25% gain on June 22, driven by investor confidence in the acquisition's long-term growth prospects.